The Shreveport Times reached out to Professor Andrew Yurochko, Carroll Feist endowed chair of viral oncology and department vice-chair of microbiology and immunology, LSUHS, with the Emerging Viral Threat lab which began processing COVID-19 samples last Wednesday.
The School of Graduate Studies offers PhD degrees in five programs, an MS degree in Biomedical Science, and a combined MD-PhD degree program. Successful applicants can enter directly into one the five programs or can enter though the Interdisciplinary Graduate Program in which students choose a mentor and program after the first semester.
The School of Graduate Studies was established as part of the LSU Medical Center (known as LSU Health Shreveport today) in 1965, with degrees offered in five basic science departments. The first class was accepted in 1974 and the first PhD degree awarded in 1978. On March 25, 2004, the Louisiana Board of Regents approved administrative separation of the School of Graduate Studies in Shreveport from the School of Graduate Studies in New Orleans. The School of Graduate Studies in Shreveport was placed under the leadership of the LSUHS Chancellor in 2004. Dr. Sandra Roerig was appointed the first Dean of the school on April 1, 2004 and served in this role until her retirement in 2017.
Working with supportive faculty mentors, our students are prepared to become biomedical scientists, contributing to advances in healthcare and biotechnology, and educators, training the next generation of basic scientists, physicians and other healthcare professionals. Learn more about our Student Achievement.
LSU Health Shreveport has established the Emerging Viral Threat (EVT) Laboratory to address the need for faster detection and processing of COVID-19 tests.
LSUHS leadership, faculty, staff, students and community supporters recently honored the continued growth of research initiatives and funding at the second annual Research Celebration event held on February 25, 2020.
Internationally recognized for his research on inflammatory vascular pathology, specifically on and the relationship between inflammation and vascular growth and function, Dr. Kevil discovered detailed mechanistic relationships between angiogenesis and inflammation.
Aphios Granted U.S. Patent for Oral Administration of Bryostatin-1 Nanoparticles for Treatment of Neurodegenerative Diseases, which was co-invented by LSU Health Shreveport professor, Dr. J. Steven Alexander.
JanOne Acquires Worldwide, Exclusive License for Promising Treatment of Peripheral Arterial Disease (PAD), TV1001SR, which was invented by LSU Health Shreveport professor and vice chancellor for research, Dr. Chris Kevil.
Praveen K. Jaiswal, PhD, a postdoctoral fellow in the Department of Biochemistry and Molecular Biology has received a prestigious Research Scholar Award for Mentored Prostate Cancer Research from the AUA Urology Care Foundation.
LSU Health Shreveport researchers recently presented preliminary findings at the American Heart Association’s Basic Cardiovascular Sciences 2019 Scientific Sessions that use of the illegal stimulant methamphetamine causes build-up of tough protein fibers in heart muscle, which may help explain the development of enlarged hearts and heart failure in users.
Zaki Al Yafeai, Dr. Celeste Wu, Dr. Shafiul Alam and Alexandre Do Couto E Silva were recognized as American Heart Association Fellowship recipients.
Christopher Pattillo, PhD, Associate Professor of Molecular and Cellular Physiology, has received a grant from the National Heart, Lung, and Blood Institute of the NIH for his five-year project, “Cellular Reductive State Regulates Arteriogenesis.”